熱門資訊> 正文
BridgeBio因卡纳万病基因治疗获得FDA RMAT资格
2024-09-11 05:15
- BridgeBio (NASDAQ:BBIO) has received FDA Regenerative Medicine Advanced Therapy designation for its AAV9 gene therapy candidate BBP-812 for the treatment of patients with Canavan disease, a fatal neurodegenerative disorder.
- The company said it plans to leverage the benefits of the designation to establish an accelerated pathway for the treatment, according to a statement.
- The therapy has also been granted Orphan Drug, Rare Pediatric Disease, and Fast Track Designations by the FDA, as well as Orphan Drug Designation by the European Medicines Agency.
More on BridgeBio Pharma
- BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
- BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum
- BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon
- BridgeBio draws bullish view at Piper on potential acoramidis nod
- Alnylam tumbles, BridgeBio gains after heart drug data
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
